WASHINGTON – Robert F. Kennedy Jr., President Trump’s choice to lead the Ministry of Health and Human Services, does not think that high drug prices are a reason to undermine the patent rights of pharmaceutical companies, he told senators after his confirmation hearings.
Whether or not the National Institutes of Health can use ‘Mars-in-Rights’ in a broader sense-one policy with which the patent rights can make drug makers whose products are dependent on federally financed research-is a controversial issue in different administrations. The authority was never used on the basis of the price of a medicine.
In response to a question from Senator Elizabeth Warren (D-Mass.) About whether he reduces the use of Mars-in-Rights to lower the prices of the medicines, RFK Jr. That “would not be appropriate use of Mars-in rights”, according to the answers obtained by Stat.
This article is exclusive to Stat+ subscribers
Unlock this article – plus daily coverage and analysis of the biotech sector – by subscribing to Stat+.
Do you already have an account? Log in
View all plans
To read the rest of this story, subscribe to Stat+.
Subscribe